Clinical trials: Cancer Unknown Primary
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
This phase II clinical trial studies how well thermal ablation and spine stereotactic radiosurgery work in treating patients with cancer that has spread to the spine (spine metastases) and is at risk for compressing the spinal…
- Conditions
- Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine
- Trial name
- NCT02713269
- Testing
- Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells.
- Conditions
- Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer, Bone Metastases, Carcinoma of the Appendix
- Trial name
- NCT00004074
- Testing
- recombinant interleukin-12, ABI-007/carboplatin/trastuzumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Cancer of Unknown Primary Site
Nivolumab/Ipilimumab in Second Line CUP-syndrome
To compare the efficacy of nivolumab plus ipilimumab in subjects with high vs. Intermediate/low TMB poor-prognosis CUP (non-specific subset) who are relapsed or refractory to platinum-based first-line chemotherapy.
- Trial name
- CheCUP (NCT04131621)
- Testing
- Nivolumab/Ipilimumab
- Where
- Germany
- Volunteers
- 194 people
- Sponsor
- University Hospital Heidelberg
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Adenocarcinoma of Unknown Primary, Adult Cholangiocarcinoma
Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer
This phase I/II trial studies the side effects of genetic analysis-guided dosing of paclitaxel albumin-stabilized nanoparticle formulation, fluorouracil, leucovorin calcium, and irinotecan hydrochloride (FOLFIRABRAX) in treating…
- Conditions
- Adenocarcinoma of Unknown Primary, Adult Cholangiocarcinoma, Gallbladder Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT02333188
- Testing
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Leucovorin Calcium, Irinotecan Hydrochloride
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Chicago
Cancer of Unknown Primary Site, Unknown Primary Cancer
Surgeon-performed Intraoperative Transoral Ultrasound for Cancer of Unknown Primary
Adult patients suspected of Squamous Cell Carcinoma of Unknown Primary (SCCUP) will be prospectively enrolled at a tertiary head \& neck cancer center at Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- Conditions
- Cancer of Unknown Primary Site, Unknown Primary Cancer, Unknown Primary, Squamous Cell Carcinoma
- Trial name
- OP-CUP (NCT05841966)
- Testing
- Transoral Ultrasound
- Where
- 2 sites in Denmark
- Volunteers
- 30 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma in Cervical Lymph Node
Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease
This early phase I trial studies how well fluciclovine F18 positron emission tomography (PET)/computed tomography (CT) works in identifying the origin of head and neck squamous cell carcinoma in patients with cancer that has…
- Trial name
- NCT03868020
- Testing
- Computed Tomography, Fluciclovine F18, Positron Emission Tomography
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer, Brain and Central Nervous System Tumors
High-dose ICE With Amifostine
The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and…
- Conditions
- Bladder Cancer, Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Extragonadal Germ Cell Tumor
- Trial name
- NCT00003657
- Testing
- filgrastim, Amifostine, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Dana-Farber Cancer Institute
Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary
Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Leukemia, Lymphoma
- Trial name
- NCT00112619
- Testing
- topotecan hydrochloride
- Where
- 11 sites in United States
- Volunteers
- 19 people
- Sponsor
- Pediatric Brain Tumor Consortium
Cancer
A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary
The goal of this clinical research study is to learn if the combination of atezolizumab and tiragolumab can help to control cancers of unknown primary. The safety and effects of this drug combination will also be studied
- Trial name
- NCT06754501
- Testing
- Atezolizumab, Tiragolumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Carcinoma, Carcinoma of Unknown Primary
Cancer Genetic Testing in Ethnic Populations
This clinical trial examines the integration of cancer genetic testing in various ethnic populations. Studying individuals and families at risk of cancer may help identify cancer genes and other persons at risk.
- Conditions
- Breast Carcinoma, Carcinoma of Unknown Primary, Central Nervous System Carcinoma, Digestive System Carcinoma
- Trial name
- NCT04475640
- Testing
- Biospecimen Collection, Genetic Testing
- Where
- 2 sites in United States
- Volunteers
- 1,800 people
- Sponsor
- Mayo Clinic
Carcinoma of Unknown Primary, Head and Neck Cancer
Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003582
- Testing
- amifostine trihydrate, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Miami
Oropharyngeal Cancer, Carcinoma
Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
This is a single institution phase II study that will enroll patients with T0-3N0-2 p16-positive oropharyngeal squamous cell carcinoma (OSCC) undergoing resection of all gross visible disease at the primary site and in the lymph…
- Trial name
- NCT06445114
- Testing
- Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Zachary Zumsteg
Head and Neck Carcinoma, Head and Neck Carcinoma of Unknown Primary
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
This clinical trial studies how well intensity modulated proton therapy (IMPT) or intensity modulated X-ray (radiation) therapy (IMRT) works after surgery in treating patients with head and neck cancer.
- Conditions
- Head and Neck Carcinoma, Head and Neck Carcinoma of Unknown Primary, Hypopharyngeal Carcinoma, Laryngeal Carcinoma
- Trial name
- NCT05075980
- Testing
- Cisplatin, Intensity-Modulated Proton Therapy, Quality-of-Life Assessment
- Where
- 9 sites in United States
- Volunteers
- 174 people
- Sponsor
- Mayo Clinic
Neoplasms, Unknown Primary
Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
This trial will investigate the combination of bevacizumab, and erlotinib in patients with adenocarcinoma or poorly differentiated carcinoma of unknown primary site.
- Trial name
- NCT00193622
- Testing
- Bevacizumab, Erlotinib
- Volunteers
- 50 people
- Sponsor
- SCRI Development Innovations, LLC
Localized Non-Resectable Adult Liver Carcinoma
Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study
This research registry studies Yttrium Y 90 resin microspheres in collecting data from patients with liver cancer not capable of being removed by surgery (unresectable) for the radiation-emitting Selective Internal…
- Trial name
- RESiN (NCT02685631)
- Testing
- Yttrium-90 Resin Microspheres
- Where
- 42 sites in United States
- Volunteers
- 1,653 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Carcinoma of Unknown Primary
Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary
It's a phase 2, single arm study of gemcitabine an docetaxel combination in patients with carcinoma of unknown primary.
- Trial name
- NCT02590055
- Testing
- gemcitabine/docetaxel combination
- Where
- South Korea
- Volunteers
- 29 people
- Sponsor
- Samsung Medical Center
MSI-H Colorectal Cancer, Melanoma
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
This is an open-label, parallel group, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab (cohorts 1 and 2) and tislelizumab (cohort 3) in monotherapy in patients with PD1-high-expressing tumors.
- Conditions
- MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma, Mesothelioma
- Trial name
- ACROPOLI (NCT04802876)
- Testing
- Spartalizumab, Tislelizumab
- Where
- Spain
- Volunteers
- 184 people
- Sponsor
- SOLTI Breast Cancer Research Group
Cancer of Unknown Primary Site
Trial of Pembrolizumab in Cancer of Unknown Primary
Abbreviated Title : CUPem Clinical Indication : A Phase II, Two-Stage, Trial of Pembrolizumab in Cancer of unknown primary Trial Type : Single Arm, non-randomised; Two-stage; Hypothesis generating Type of control : None Route of…
- Trial name
- CUPem (NCT03752333)
- Testing
- Pembrolizumab
- Where
- 3 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- Imperial College London